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Abstract 
Antithrombin (AT) is the principal inhibitor of thrombin in human plasma, and a member of the serine proteinase (serpin) family of proteins. 
Previously, we have described a point mutation in the human AT gene that converted amino acid 392 from glycine to aspartic acid which was 
associated with thrombotic disease in a Swedish family [(1992) Blood 79, 1428-14341. This observation prompted us to investigate the consequences 
of other substitutions at this position, termed P2 with respect o the reactive centre. Site-directed mutagenesis was employed to generate seven mutants 
(Pro, Met, Gln, Val, Lys, Glu, and Asp), whose properties were compared with wild-type recombinant AT, following in vitro transcription and cell-free 
expression in a rabbit reticulocyte lysate system. With only one exception, the variant forms were less active than the wild-type in forming complexes 
with either a-thrombin, factor Xa, or trypsin. Hydrophobic (Val) or negatively charged (Asp or Glu) substitutions were particularly disruptive, in 
that these variants exhibited less than 10% wild-type antithrombin or antitrypsin activity. In contrast, the formation of complexes with the various 
proteases of the Pro variant was essentially unimpaired. We conclude that the P2 residue of AT plays a role in optimal presentation of the reactive 
centre to its cognate protease, and propose that the observed requirement of Gly or Pro at this position is suggestive of a bend in the polypeptide 
backbone that aids in this presentation. 
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1. Introduction 
Antithrombin (AT), or antithrombin III, is the princi- 
pal natural inhibitor of thrombin and other procoagu- 
lant serine proteases found in plasma [1,2]. This 60 kDa 
glycoprotein is a suicide inhibitor of its cognate pro- 
teases, and a member of the serine proteinase (serpin) 
family of proteins [3,4]. Attack by the protease at the 
reactive centre of AT, Arg393-Ser394, leads not only to 
cleavage of AT, but also to the formation of a stable 
AT-protease complex [5]. In the complex, a covalent 
ester bond links the carboxyl group of AT residue Arg393 
and the hydroxyl group of the active site serine of the 
protease [6]. 
Congenital deficiencies of AT are associated with an 
increased risk of thrombotic disease [7,8]. Qualitative 
(type II) deficiencies result from alterations to single 
amino acid residues in the protein product of the mutant 
allele [9]. Recently, we identified a novel mutation of AT, 
G392D, in a Swedish kindred with familial thrombosis 
[lo], AT-Stockholm. In the present study, we examined 
the consequences of substitutions other than Asp at this 
position, a single residue N-terminal to the reactive cen- 
tre, by site-directed mutagenesis and expression in a cell- 
free system. Our results suggest hat Gly or Pro residues 
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are required at this location for optimal inhibition of 
both thrombin and two other serine proteases, perhaps 
because of the helix-breaking potential of these amino 
acids. 
2. Materials and methods 
2 1. Materials 
Human a-thrombin (> 2500 NIH units/mg; > 99% active) was kindly 
provided by Dr. J. Fenton (New York State Division of Biologicals, 
Albany, NY). Human Factor Xa was the generous gift from Dr. F.A. 
Ofosu, McMaster University, while trypsin was purchased from Sigma 
Chemical Company (St. Louis, MO). All restriction, DNA modifying 
enzymes, and T7 sequencing kits were from Pharmacia LKB Biotech- 
nology (Baie d’Urf&, QC). Bethesda Research Laboratories (BRL) 
(Burlington, ON) was the supplier of E. coli DHSa cells competent for 
transformation. Promega Biotec (Madison, WI), was the source of 
rabbit reticulocyte lysate. A kit for site-directed mutagenesis was pur- 
chased from Amersham (Oakville, ON). The thrombin inhibitor D- 
phenylalanyl-L-prolyl-arginine chloromethyl ketone (PPACK) (> 99% 
active) was purchased from Calbiochem (Mississauga, ON), and the 
serine protease inhibitor phenylmethylsulfonyl fluoride (PMSF) from 
Sigma (St. Louis, MO). Translation grade [“Slmethionine (>lOOO Ci/ 
mmol, 10 @i/pi) was purchased from New England Nuclear (Lachine, 
QC). Protein molecular weight standards were from Bio-Rad Labora- 
tories (Oakville, ON). Oligonucleotides were synthesized at the Institute 
for Molecular Biology and Biotechnology, McMaster University, Ha- 
milton, ON. All other chemicals and reagents were of the highest qual- 
ity available. 
2.2. Site-directed mutagenesis 
The previously described [I l] phagemid pGEM-3Zf(+)-AT-III,,,, 
was used to provide single stranded starting material for mutagenesis, 
which was carried out using the gapped duplex method in accordance 
with the kit manufacturer’s instructions (Amersham). The degenerate 
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oligodeoxynucleotide primers 5’-TGATTGCT(ACG)(ACT)(ACGT)- 
CGTTCGCT-3’ and 5’.TGATTGCT(AC)(ACT)(AG)CGTTCGCT-3’ 
were employed, and individual clones were characterized by double- 
stranded sequencing of the target codons and neighbou~ng DNA. 
Resulting pIasmlds differing from wild-type pGE~3zf(+)ATIII, 432 at 
position 392 were designated pCEM3zf(+)ATIII,,,,,,,,,, where X rep- 
resents the single-letter code for the new amino acid residue. 
2.3 In vitro transcription and cell-free translation 
In vitro transcription reactions employing T, polymerase were per- 
formed as described [12,13], following linearization of plasmid tem- 
plates with EcoRI. The resulting AT-derived mRNA transcripts were 
translated m an mRNA-dependent rabbit reticulocyte lysate as de- 
scribed previously 112,131, except hat the reaction mixture was supple- 
mented with oxidized glutathione to a final concentration of?.5 mmol/l. 
2.4 Protease-complexmg assavs 
The reaction of thrombin with cell-free derived AT polypeptides was 
monitored as described previously [12,13]. Briefly. in vitro translation 
mixtures were diluted 1: 1 with TBS, dialyzed overnight against he same 
buffer, aliquoted and flash-frozen at -70°C. Followmg determination 
of the trichloroacetic acid precipitable counts, concentrations of trans- 
lated AT protein species were normalized by the addition of translation 
mixtures to which no RNA had been added, and reacted with thrombin 
or factor Xa at a final con~ntration of 1.0 pM. Trypsin was employed 
at a final concentration of 200 nM, m order to maximize complex 
formatlon and minimize cleavage at sites other than the reactive centre. 
Reactions were stopped by the addition of PPACK in the case of 
thrombin. and PMSF in the case of factor Xa and trypsin. 
? 5 Gel analysis and densttometr) 
Electrophoretic separation of radiolabeled proteins under reduced or 
non-reduced conditions, and fluorography of dried gels was done as 
previously described [l 1 J. Densitometric scanning of autoradiograms 
was performed using an Ultroscan XL apparatus (LKB, Bromma, 
Sweden). 
3. Results 
Site-directed mutagenesis was employed in order to 
generate forms of the antithrombin cDNA in which 
codon 392 (GGA, Gly) had been altered. Sequencing of 
a total of 60 clones, derived from mutagenesis reactions 
that used two separate mixtures of oligodeoxynucleo- 
tides that were degenerate at codon 392, yielded seven 
different mutants: Asn (AAC), Asp (GAC), Glu (GAA), 
A B 
-TAT 
Lys (AAA), Met (ATG), Pro (CCA), and Val (GTA). 
The frequency of appearance of the different mutants 
was as expected, in that those resulting from a single 
nucleotide mismatch were more common than those re- 
sulting from double or triple mismatches. 
3.2. Reaction of cell-free derived AT with serine proteases 
ln order to ascertain the effect of various amino acid 
substitutions on the biological activity of the AT protein, 
we exploited a cell-free expression system that has been 
used extensively in our laboratory for the study of nor- 
mal recombinant and mutant AT molecules [I l-131. Fol- 
lowing in vitro transcription of pGEM-AT-III, +?, 
translation of the resulting mRNA in a messenger- 
dependent rabbit reticulocyte lysate, in the presence of 
[%]methionine, leads to the synthesis of labelled AT 
polypeptides. These molecules are the major radiola- 
belled proteins in the reaction mixture which can be 
visualized following SDS-PAGE and fluorography with- 
out the need for fractionation or i~unoprecipitation. 
Addition of excess unlabelled thrombin results in the 
formation of a covalent thrombin-AT complex, as shown 
by the appearance of a thrombin-dependent 80 kDA 
band (Fig. I, panel A). Similar complexes can be ob- 
served following the reaction of cell-free derived AT with 
both factor Xa (Fig. 1, panel B) and trypsin {Fig. 1, panel 
C). In the latter case, five-fold less trypsin than the other 
two serine proteases was employed, in order to minimize 
cleavage at arginyl residues other than the reactive cen- 
tre. In addition to the TAT species, in some reactions two 
other products with more rapid electrophoretic mobility 
than full-length AT can be seen: a protease independent 
band that derives from internal inititiation at Met17 
which does not cont~bute significantly to TAT forma- 
tion, and a protease-dependent band resulting from AT 
cleavage. 
3.3. Reaction of the AT 392 variants with a-thrombin 
We first analyzed the reaction with thrombin of the 
family of AT mutants differing at residue 392. In order 
c 
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Fig 1. Reaction of cell-free derived AT with serine proteases. f5S-labelled AT molecules were generated in rabbit reticulocyte translation reactions, 
and reacted for various times (shown below each panel, m minutes) with ol-thrombin (Panel A), factor Xa (Panel B), or trypsm (Panel C). PosItions 
and sizes (in kDa) of molecular weight standards are shown at left; positions of thrombin-antithrombin (TAT), factor Xa-antithrombin (XaAT), and 
trypsin-antithrombin (TRAT) complexes are indicated. as is the position of full-length cell-free derived AT (open arrowheads). Autoradlograms of 
10% SDS-polyacrylamide gels are shown. 
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Fig. 2. Reaction of cell-free derived AT variants differing only at residue 392. Cell-free derived AT species containing the various substitutions at 
residue 392, identified at the top of each panel, were reacted with a-thrombin as in Fig. 1. The migration position of the TAT complex is highlighted 
(C), as is the position of full-length cell-free derived AT (open arrowheads), and that of thrombin-cleaved AT (open circles). 
to minimize variation between batches of reticulocyte 
lysate and differences between synthesis reactions per- 
formed at different times, all eight forms of recombinant 
human AT were synthesized, diluted, dialyzed, aliquoted 
and flash-frozen at the same time. Total TCA-precipita- 
ble counts were normalized to the lowest incorporation 
reaction, and AT proteins reacted with excess (1.0 PM) 
thrombin for 0,0.5, or 5 minutes. The resulting autoradi- 
ograms are shown in Fig. 2, and their quantitation in 
Table 1. 
Comparison of the proportion of the input AT found 
in TAT complexes at five minutes revealed that the AT 
mutants could be grouped into three categories, accord- 
ing to their reactivity with thrombin: minimally impaired 
(> 60% wild-type reactivity); moderately impaired 
(> 25%. < 60% wild-type reactivity); and severely im- 
paired (< 10% wild-type reactivity). Based on these crite- 
ria, the Pro and Gln mutants showed minimal impair- 
ment. the Lys and Met variants moderate impairment, 
and the Asp, Glu, and Val variants severe impairment. 
Reaction with thrombin can also lead to the production 
of a cleaved form of AT, with increased mobility under 
reducing conditions (Fig. 2, open circle). This product 
was detectable only in reactions with the wild-type re- 
combinant AT or the Pro variant. In the latter case, this 
product was generated more rapidly, and in greater 
amounts, than in the former. 
3.4. Reaction of the AT 392 variants with the other serine 
proteases 
In order to determine if the decreases observed in reac- 
tivity with thrombin were specific to the reaction of AT 
with this procoagulant protease, similar experiments 
were performed with Factor Xa and trypsin, and the 
Table 1 
Quantification of AT-protease complex formation 
Alteration % Relative complex Side-chain characteristic 
formation 
IIa Xa Trypsin Average Hydropathy 
volume index 
None (WT) 100 100 100 66 -0.4 
G392 P 81 103 93 129 -1.6 
G392 Q 66 62 81 161 -3.5 
G392 K 28 43 32 171 -3.9 
G392 M 26 21 11 170 1.9 
G392 D 10 4 10 125 -3.5 
G392 V I 10 11 142 4.2 
G392 E I 35 I 155 -3.5 
Experiments identical to those depicted in Fig. 2 were performed, ex- 
cept that either thrombin (Ha), factor Xa, or trypsin were employed. 
Complex formation after 5 min of incubation was determined by den- 
sitometric scanning of autoradiograms, and the results expressed as % 
complex formation relative to that of the cell-free derived wild-type AT. 
Side-chain volume (in cubic angstroms) and hydropathy index (arbi- 
trary units) are from [19] and [20] respectively. 
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results quantified (Table 1). Very similar results to those 
seen with thrombin were observed in the case of trypsin, 
in terms of the ranking of variants and the extent of 
mutant inhibitor dysfunction. The results with Factor Xa 
were also similar, with the exception that the Glu substi- 
tution affected this reaction to a lesser extent than for the 
other two proteinases. The reactivity of the Pro variant 
with either factor Xa or trypsin was essentially un- 
changed relative to wild type. 
4. Discussion 
We have investigated the effects of amino acid substi- 
tutions at the P2 position of AT. Previously we had 
shown that altering this residue to Asp resulted in a loss 
of AT function, both in an AT-deficient kindred and 
with the equivalent cell-free-derived recombinant prod- 
uct [lo]. The present study has demonstrated that not 
only negatively charged (Asp or Glu) but also hydropho- 
bic (Val), neutral (Met or Gln), or positively charged 
(Lys) substitutions, at this position, also reduce the abil- 
ity of AT to form complexes with both thrombin and two 
other serine protease inhibitors, factor Xa and trypsin. 
Examination of Table 1 suggests that the reactivity of 
the different mutants with their cognate proteases does 
not correlate with residue size or hydrophobicity. 
Rather, both charged and strongly hydrophobic residues 
are not favoured. The wild-type Gly and Pro residues 
gave the most functional recombinant AT products. In- 
deed, the Pro variant exhibited more rapid and more 
extensive cleavage by thrombin than did the wild-type. 
Densitometric scanning of the full-length AT species 
present before and after incubation with thrombin 
showed that only 17% of the Pro variant remained un- 
reacted, as compared to 57% of the wild-type (Fig. 2). 
However, since protease inhibition depends upon serpin 
complex formation, our data suggests that the Pro vari- 
ant is minimally impaired in its function, rather than 
supranormal, as its cleavage behaviour might suggest. 
Interestingly, both Gly and Pro residues are frequently 
found at /?-turns in proteins, and are therefore thought 
of as helix-breaking residues [14,15]. While neither AT 
nor any other inhibitory serpin has been crystallized, the 
crystal structure of the related serpin, ovalbumin, has 
been solved. The reactive centre loop of the protein is 
found as a three-turn a-helix, terminating with the Pl- 
Pl’ bond [16]. It has been suggested that the inhibitory 
serpins, although exhibiting mobile conformations of 
this region, have retained the ability to fold this region 
into a similar a-helix [17]. If this is the case, then the 
requirement for helix-breaking residues at P2 becomes 
obvious. On the other hand, the observed preference for 
Gly or Pro residues at this position of AT may simply 
indicate that these residues interact with the active site 
of the attacking protease most effectively. In this regard, 
it is known that Phe-Pro-Arg-CH,Cl is a more efficient 
inhibitor of thrombin than chloromethyl ketones lacking 
the Pro residue at P2 [18]. 
In conclusion, the results presented here suggest hat 
residue 392 of AT (P2) contributes to the optimal presen- 
tation of the adjacent reactive centre to its cognate pro- 
teases; this presentation may involve the maintenance of 
a B-turn or other helix-breaking structure. Other substi- 
tutions could both obscure this necessary structure and 
directly repel the incoming protease’s active site. 
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